Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer
Zhehai Wang(Shandong Tumor Hospital), Minmin Li(First Affiliated Hospital of Jinan University), Huan Shi(Shandong University), Huihui Li(Sichuan University), Jie Liu(Fujian Medical University), Liyan Liu, Xia Zhang(Army Medical University), Changzheng Li(Sun Yat-sen University), Jun Guo(Shandong Tumor Hospital), Lin Liu(Heilongjiang University of Chinese Medicine), Chao Xie(Allen Institute for Brain Science), Shu Fang(Peking University), Wenwen Sun(Shandong First Medical University)
Cited by 21
Related Papers
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adaptive genic evolution in the <i>Drosophila</i> genomes
|Proceedings of the National Academy of Sciences|2007|227